Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Synthesis, characterization and anticonvulsant activity of new azobenzene-containing VV-hemorphin-5 bio photoswitch.

Todorov PT, Peneva PN, Georgieva SI, Tchekalarova J, Vitkova V, Antonova K, Georgiev A.

Amino Acids. 2019 Mar;51(3):549-563. doi: 10.1007/s00726-018-02691-1. Epub 2019 Jan 2.

PMID:
30604096
2.

Diagnostic value of musculoskeletal ultrasound in patients with low back pain - a review of the literature.

Todorov PT, Nestorova R, Batalov A.

Med Ultrason. 2018 Feb 4;1(1):80-87. doi: 10.11152/mu-1245. Review.

3.

Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.

Cole DK, Sami M, Scott DR, Rizkallah PJ, Borbulevych OY, Todorov PT, Moysey RK, Jakobsen BK, Boulter JM, Baker BM, Yi Li.

Front Immunol. 2013 Jun 26;4:168. doi: 10.3389/fimmu.2013.00168. eCollection 2013.

4.

Monoclonal TCR-redirected tumor cell killing.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK.

Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764.

PMID:
22561687
5.

Cytotoxic activity of new racemic and optically active N-phosphonoalkyl bicyclic β-amino acids against human malignant cell lines.

Todorov PT, Wesselinova DW, Pavlov ND, Martinez J, Calmes M, Naydenova ED.

Amino Acids. 2012 Oct;43(4):1445-50. Epub 2012 Jan 12.

PMID:
22237947
6.

Synthesis and biological activity of new series of N-modified analogues of the N/OFQ(1-13)NH2 with aminophosphonate moiety.

Todorov PT, Mateeva PI, Zamfirova RN, Pavlov ND, Naydenova ED.

Amino Acids. 2012 Sep;43(3):1217-23. doi: 10.1007/s00726-011-1177-7. Epub 2011 Dec 6.

PMID:
22143428
7.

Synthesis and biological activity of novel small peptides with aminophosphonates moiety as NOP receptor ligands.

Naydenova ED, Todorov PT, Mateeva PI, Zamfirova RN, Pavlov ND, Todorov SB.

Amino Acids. 2010 Nov;39(5):1537-43. doi: 10.1007/s00726-010-0624-1. Epub 2010 May 25.

PMID:
20499257
8.

Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity.

Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SM, Berger MR.

Cancer Chemother Pharmacol. 2011 Jan;67(1):13-25. doi: 10.1007/s00280-010-1273-5. Epub 2010 Feb 23.

PMID:
20177898
9.

Recent synthesis of aminophosphonic acids as potential biological importance.

Naydenova ED, Todorov PT, Troev KD.

Amino Acids. 2010 Jan;38(1):23-30. doi: 10.1007/s00726-009-0254-7. Epub 2009 Feb 20. Review.

PMID:
19229586
10.
11.

Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.

Naydenova ED, Todorov PT, Topashka-Ancheva MN, Momekov GTs, Yordanova TZ, Konstantinov SM, Troev KD.

Eur J Med Chem. 2008 Jun;43(6):1199-205. Epub 2007 Sep 11.

PMID:
17950497
12.

Stable, soluble T-cell receptor molecules for crystallization and therapeutics.

Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P, Jakobsen BK.

Protein Eng. 2003 Sep;16(9):707-11.

PMID:
14560057
13.
14.

Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.

Hussey HJ, Todorov PT, Field WN, Inagaki N, Tanaka Y, Ishitsuka H, Tisdale MJ.

Br J Cancer. 2000 Jul;83(1):56-62.

15.

Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor.

Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC.

Br J Surg. 2000 Jan;87(1):53-8.

PMID:
10606911
16.

Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361).

Todorov PT, Field WN, Tisdale MJ.

Br J Cancer. 1999 Aug;80(11):1734-7.

17.

Purification and characterization of a tumor lipid-mobilizing factor.

Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ.

Cancer Res. 1998 Jun 1;58(11):2353-8.

18.
19.

Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.

Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ.

Br J Cancer. 1997;76(5):606-13.

20.

Induction of muscle protein degradation and weight loss by a tumor product.

Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ.

Cancer Res. 1996 Mar 15;56(6):1256-61.

21.

Catabolic factors in cancer cachexia.

Tisdale MJ, McDevitt TM, Todorov PT, Cariuk P.

In Vivo. 1996 Mar-Apr;10(2):131-6.

PMID:
8744791
22.

Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans.

McDevitt TM, Todorov PT, Beck SA, Khan SH, Tisdale MJ.

Cancer Res. 1995 Apr 1;55(7):1458-63.

Supplemental Content

Loading ...
Support Center